Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo-controlled study of interferon-?1a in relapsing-remitting multiple sclerosis-Reference-Cited by-同舟云学术

Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo-controlled study of interferon-?1a in relapsing-remitting multiple sclerosis

Published:1999-08 Issue:2 Volume:46 Page:197-206
ISSN:0364-5134
Container-title:Annals of Neurology
language:en
Short-container-title:Ann Neurol.

Author:

Li David K. B.,Paty Donald W.,

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Reference24 articles.

1. Systemic lymphoblastoid interferon therapy in chronic progressive multiple Sclerosis. I. Clinical and MRI evaluation

2. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial

3. Interferon beta-lb in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial

4. Chronic systemic high‐dose recombinant interferon alfa‐2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing‐remitting multiple sclerosis

5. Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis.

Cited by 316 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Routine MR Imaging Protocol and Standardization in Central Nervous System Demyelinating Diseases;Neuroimaging Clinics of North America;2024-08

2. Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives;Neurology and Therapy;2024-01-11

3. Disease‐modifying therapies in multiple sclerosis: A focused review of rituximab;Basic & Clinical Pharmacology & Toxicology;2023-09-20

4. Interferon beta-1a sc at 25 years: a mainstay in the treatment of multiple sclerosis over the period of one generation;Expert Review of Clinical Immunology;2023-09-11

5. The evolution of interferon therapy in multiple sclerosis;Neurology, Neuropsychiatry, Psychosomatics;2023-08-21